This study was to investigate the interaction between opposite result was obtained for clinic BP at trough, whereby the addition of amlodipine to perindopril low doses of perindopril (2 mg daily) and amlodipine (2.5 mg daily) on ambulatory blood pressure (BP), clinic reduced erect systolic BP (P = 0.036) and both supine and erect diastolic BP (P = 0.038) whereas the addition BP, serum angiotensin-converting enzyme (ACE), plasma levels of renin (PRA), angiotensin II (Ang II), of perindopril to amlodipine was without effect. The addition of perindopril to amlodipine decreased aldosterone, and atrial natriuretic peptide (␣-h ANP) in subjects with essential hypertension. The study design serum ACE by 72% and increased PRA two-fold, without change in plasma levels of Ang II, aldosterone or ␣-h was a parallel, two-period, placebo-controlled, doubleblind crossover design, with 11 subjects receiving per-ANP. The addition of amlodipine to perindopril increased plasma aldosterone 1.7-fold but did not affect indopril and 10 receiving amlodipine during the run-in phase.
Introduction
for example, interference with binding to plasma True synergism in clinical anti-hypertensive therprotein or changes in hepatic blood flow due to a apy, over and above a simple additive effect, is not calcium channel blocker might alter the bioavaileasy to detect reliably. Numerous clinical studies ability of ACE inhibitors. have demonstrated beneficial additive effects
In the present study, an attempt has been made to between angiotensin-converting enzyme (ACE) determine whether a long-active ACE inhibitor and inhibitors and calcium antagonists in hypertensive a long-acting calcium antagonist, both given in patients. [1] [2] [3] [4] [5] [6] [7] [8] However, synergism between these two doses below the dosage generally recommended for classes of anti-hypertensive agent is theoretically a therapeutic effect, can result in a significant antipossible. Potentiation of the calcium antagonist verhypertensive effect when in combination. Collateral apamil by the ACE inhibitor enalaprilat has been evidence of efficacy at the doses given as well as demonstrated in rats. 9 The anti-hypertensive possible indicators of the mechanism of any drug activity of ACE inhibitors, well known to be interaction, was sought by measurement of blood enhanced by diuretics, could be potentiated by the levels of ACE, atrial natriuretic peptide (␣-h ANP), natriuretic action of calcium antagonists. 10 A pharmplasma renin activity (PRA), aldosterone and angiotensin II (Ang II).
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The study was of a parallel, two-period, placebo- 
Results
of the run-in period, one because of a side effect (headache) and one because the patient withdrew The characteristics of subjects are shown in Table 1 . There were no significant differences between consent. The study was approved by the institutional ethics committee.
Groups A and B in mean values for age, body weight or BP. Gender distribution was similar. Six patients Patients attended clinic between 08.00 and 11.00 hours every 2 weeks during the randomised period.
in Group A were randomised to receive amlodipine placebo from week 0 to week 4 of the first phase and Prior to entry, a complete clinical examination was performed, including a blood count, and measureactive amlodipine (together with continued active perindopril), from week 0 to week 4 of the second ment of serum electrolytes, creatinine, urate, glucose, cholesterol, triglycerides, protein, bilirubin phase. The other five patients in Group A received active amlodipine in the first phase and amlodipine and transminases. Patients with serum creatinine greater than 0.15 mmol/L or other abnormal bioplacebo in the second phase. In Group B, five patients were randomised to placebo for the first chemical or haematological values were excluded, as were those with secondary hypertension. The biochemical and haematological tests were repeated at Table 1 Characteristics of patient groups at randomisation week 4 of each of the two randomised phases. Blood (week 0) (30 ml) was also taken at these times for measurement of serum ACE, plasma ANP, Ang II, aldos- ings taken by the same observer throughout, which
Mean supine blood pressure (mm Hg)
were obtained at the trough of plasma drug concensystolic 148 (2) 151 (4) tration. In the week prior to the week 4 visit of both diastolic 98 (2) 96 (1) phases, ambulatory and night-time BP was meas- Medical Instruments Inc; Raleigh NC, USA) at phase followed by active perindopril for the second, were analysed separately. When Group B was analysed separately, a drug effect (P = 0.028) was found. and five patients were randomised to active perindopril followed by placebo.
A significant drug effect was also obtained when SBP or DBP in Group B were analysed separately (P = 0.027 and P = 0.049, respectively). No sequence Ambulatory and night-time blood pressure effects were found in these analyses. Figure 1 shows the results of automated BP recordings in the 10 patients of Group A and the nine Clinic blood pressure patients of Group B in whom the monitoring process was satisfactory during both the placebo and active
In Figure 2 are shown the results for clinic measurements of SBP and DBP in Groups A and B. When phases. In two patients, data capture was insufficient for analysis. In both groups, there was a sigthese groups were analysed together, using all data for weeks 2 and 4 of each crossover phase (both nificant nocturnal dip, with systolic BP (SBP) and diastolic BP (DBP) lower between 23.00 and 07.59 groups, SBP and DBP -both supine and erect), a significant drug effect (P = 0.020) was found. There hours than in the daytime periods. By analysis of variance, in Groups A and B combined the was no sequence effect. When Group A was analysed separately, there was a significant drug effect additional drug had no significant effect when all data was used: both groups; periods a, b and c; SBP (P = 0.046); when SBP (supine and erect) was analysed separately, the drug effect was not significant. and DBP. When Group A was analysed separately there was no significant added drug effect. The same Separate analysis of supine SBP and erect SBP in Group A showed that the drug effect was significant result was obtained when SBP and DBP in Group A serum ACE. For PRA the addition of amlodipine to perindopril had no effect, whereas addition of perin-* Phase 2 significantly different from phase 1 (P Ͻ 0.02).
dopril to amlodipine increased PRA. Addition of amlodipine to perindopril increased plasma aldosterone concentration, whereas addition of perindopril to amlodipine was without such effect. However, the plasma aldosterone levels for the perindopril-amlodipine combination in Group A Group B. No significant sequence effects were obtained in analysis of the hormonal data. were not statistically significantly different from the aldosterone levels for combination therapy in Group No significant changes in heart rate were observed in either group and no side effects attributable to the B. There were no changes in plasma Ang II or in plasma ␣-h ANP concentration in either Group A or added active medication were seen in either group. the decapeptide), cumulation of angiotensin metab-
Discussion
olites and generation of true Ang II by ACE-independent pathways.
18,19
Previous studies have indicated that perindopril 2 mg once daily and amlodipine 2.5 mg once daily By contrast, the addition of amlodipine to perindopril increased plasma aldosterone, which could are sub-therapeutic or minimally effective dosages of these drugs as single-agent therapy for hypertenhave tended to counter any anti-hypertensive effect the combination may otherwise have had. The sion. In a dose-response study of perindopril, 13 a dose of 2 mg/day given for 12 weeks to 62 patients mechanism of the aldosterone increase in Group A is unknown. There is considerable evidence that with essential hypertension produced changes at trough (24-h post-dose) in SBP and DBP, respectamlodipine alone does not influence plasma aldosterone 16, 20 suggesting that the effect of amlodipine ively, of −2.7 and −4.5 mm Hg. These changes were not significantly different from the corresponding observed in Group A was dependent upon pre-existing ACE inhibition. A potential pharmacokinetic effects of placebo (−0.7 and −1.8 mm Hg), whereas the changes with 4, 8 or 16 mg/day were greater than explanation is that amlodipine, which has a high affinity for protein, 21 might have displaced perindowith placebo. In this study, 6-h post-dose measurements were also made, and again showed changes prilat by non-specific binding to ACE. In that case, circulating and tissue ACE would increase, with a in SBP and DBP (−7.2 and −7.5 mm Hg) with the 2/mg/day dose which were not significantly differconcomitant increase in adrenocortical ACE, AII and aldosterone production, explaining the observed ent from placebo (−4.8 and −2.9 mm Hg, respectively). Other dose-response studies with perrise in plasma aldosterone. Against this possibility is that serum ACE was not found to be significantly indopril 14 have also shown minimal anti-hypertensive effects with the 2 mg of dose, of borderline sigincreased in Group A at trough (24 -27 h after the last dose of amlodipine), although it is conceivable nificance.
In a dose-response study of amlodipine, 15 that it was increased at peak during the ambulatory BP recording. 2.5 mg/day given for 4 weeks to 46 patients with essential hypertension produced changes at trough Whatever the mechanism, our data are consistent with the hypothesis that the interaction was depenin supine SBP and DBP of −10.1 and −6.4 mm Hg, respectively. These changes were greater than those dent on the pre-existing therapy. It would be of interest to formally test this hypothesis in a fourwith placebo (−4.1 and −3.6 mm Hg) and the differences were of borderline significance (P Ͻ 0.05).
period crossover design in order that the different interactions (perindopril added to amlodipine and Amlodipine 5 mg/day produced changes of −17.1 and −9.1 mm Hg, respectively, which were highly amlodipine added to perindopril) could be studied on ambulatory BP in the same subjects. significant (P Ͻ 0.001) against placebo. A recent review has reported that the minimum effective Contrasting results were obtained with regard to the effects of adjunctive therapy on BP measured at dose of amlodipine is 2.5 to 5 mg/day. 16 In the present study, we did not obtain data for the clinic visits. The addition of perindopril to amlodipine had no effect on clinic BP values, either the anti-hypertensive effects of either perindopril or amlodipine alone, for the patients included were in the supine or erect posture. These observations could simply relate to an insufficient duration of receiving sustained therapy with one or the other of these drugs at the time of their study entry. Instead, action of the 2 mg dose of perindopril given 24 -27 h earlier, for 4 mg is the lowest dose that has been we determined the effects of adding one drug to the other when both were given in borderline sub-therashown to have a clear BP lowering effect 24 h after administration. 13, 22 However, inspection of the time peutic dosages. As the doses of drugs used were low and the numbers of available subjects rather small, block of ambulatory BP from 23.00-07.59 h ( Figure  1 : Group B, block c) suggests that there was no dima parallel, two-period, crossover design was employed so as to optimise the power of the study.
inution in the hypotensive effect in the period immediately prior to the clinic visits. Therefore, the However, it is acknowledged that more reliable results would have been expected from a larger possibility remains that the sympathetic neural activation implicit in waking, rising and travelling to study group.
We found that ambulatory BP was decreased the clinic may have overcome any residual effect of perindopril; such an effect may have been well when perindopril was added to amlodipine, but not when amlodipine was added to perindopril. These maintained during sleep because of interaction between the ACE inhibitor and the known heightresults could simply reflect more effective reduction of BP by 2 mg perindopril than by 2.5 mg amlodipened activity of the renin-angiotensin system during rapid eye movement (REM) sleep.
23
ine. However, the possibility must be considered that the interaction between perindopril and amlodConversely, the addition of amlodipine to perindopril produced a fall in erect BP at clinic, but had ipine was determined by baseline therapy.
The addition of perindopril to amlodipine no effect on ambulatory BP. Apart from the fact that clinic BP values were higher than ambulatory, there decreased ACE activity and produced a reflex increase in PRA 17 together with a fall in ambulatory is no ready explanation for this apparent anomaly. Thus, we speculate that there may have been a clinic BP. Plasma AII did not fall. However, it is well known that immunoreactive Ang II levels fail to component to BP, perhaps expressing higher sympathetic nervous activity and vascular resistance in decrease after ACE inhibition; the reasons include reflex rise in angiotensin decapeptide (together with the morning hours, 24 which was more effectively reduced by amlodipine than by perindopril. the minor cross-reactivity of the assay antibody for 
